CAS: 28733-43-9; 5-Bromonicotinamide

相似化合物

303031-43-8 35590-37-5 135124-70-8

上下游产品

5-溴吡啶-3-羰酰氯 5-Bromonicotinoyl Chloride 39620-02-5
5-溴烟酸 5-Bromonicotinic Acid 20826-04-4

5-溴烟腈置于水体系中,化学反应 1.0H,以90%的收率获得5-溴烟酰胺
参考文献:在无碱条件下,支持的金纳米颗粒催化的微波辅助水合将腈转化为酰胺
标题:在无碱条件下,支持的金纳米颗粒催化的微波辅助水合将腈转化为酰胺
摘要:聚苯乙烯负载的金(au @ Ps)纳米粒子是通过还原沉积法合成的,并具有紫外可见,Xrd,Tem,Saed,Edx和xps研究的特征.在微波辐射下,Au @ Ps用作催化剂将腈在水中水合成酰胺.发现几种官能化的芳族,杂环和脂族腈可用于合成相应的酰胺,而无需通过碱,配体和载体活化水.在水介导的反应条件下,该催化剂的易于回收,可忽略不计的沥滤和多达八次运行的可回收性是其优点.
Doi:10.1002/adsc.201600199

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-7612064-B2
优先权日:2003-05-26
标题:Sulfopyrroles
发明人：EBERLE MARTIN; ERMERT PHILIPP; OBRECHT DANIEL; LACH FRANK; LUTHER ANATOL; BACHMANN FELIX; STREBEL ALLESSANDRO
权利人:TAKEDA PHARMACEUTICAL
摘要:The invention relates to compounds of formula (I) wherein R 1 represents aryl, aralkyl or heteroaryl, R 2 is aryl or heteroaryl and R 3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.